Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma Europe Ltd
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects with Intra-abdominal Infections - A Multicentre, Randomized, Double-Blind Study
assess the incidence of invasive candidiasis at EOT assess the time to invasive candidiasis at EOT
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Europe Ltd. (APEL)
Update Il y a 4 ans
A study in patients with metastatic prostate cancer to assess how the drug Eligard®, affects certain markers in blood and urine, which are indicators for the disease. Een onderzoek in patiënten met uitgezaaid prostaatkanker om te bepalen hoe het geneesmiddel Eligard®, bepaalde markers in bloed en urine, die indicatief zijn voor de ziekte, beinvloedt
To explore the effect of Eligard® on the following prostate cancer biomarkers: • Testosterone in serum • Prostate Specific Antigen (PSA) in serum • Prostate Cancer Antigen (PCA3) in urine • PSA m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
Investigation of the suitability of an alternative pretreatment - tramadol - for Qutenza. Lidocaine is currently the approved pretreatment before application of Qutenza (for the treatment of peripheral neuropathic pain). Tramadol will be tested against lidocaine
To evaluate the tolerability of QUTENZA treatment when applied after pre-treatment with topical lidocaine or oral tramadol.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A trial comparing combination treatment (solifenacin plus mirabegron) with one treatment alone (solifenacin)
To evaluate the efficacy of solifenacin 5 mg plus mirabegron 50 mg versus solifenacin 5 mg monotherapy
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3